Replimune Group Stock

Replimune Group Equity

The The Equity of Replimune Group (REPL) as of Aug 11, 2026 is 166.16 M USD. In the previous year, The Equity was 415.84 M USD — a change of -60.04% (lower).

Equity

166.16 MUSD

YoY

-60.04%

Last updated:

In 2026, Replimune Group's equity was 166.16 M USD, a -60.04% increase from the 415.84 M USD equity in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Replimune Group Stock analysis

What does Replimune Group do? Replimune Group Inc is an American biotechnology company based in Woburn, Massachusetts. The company focuses on the development of therapeutics for cancer treatments through the application of oncolytic viruses. Replimune Group is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Replimune Group's Equity

Replimune Group's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Replimune Group's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Replimune Group's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Replimune Group's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Replimune Group’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Replimune Group stock

The Equity of Replimune Group is 166.16 M USD in 2026.

The Equity of Replimune Group changed from 415.84 M USD to 166.16 M USD, representing a -60.04% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Replimune Group since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Replimune Group historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Replimune Group

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Replimune Group